The new oral angiotensin II antagonist olmesartan medoxomil: A concise overview

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S13-S16

  Brunner, H R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Efficacy; Olmesartan medoxomil; Pharmacokinetics; Safety; Tolerability

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIGOXIN; DRUG METABOLITE; GAMMA GLUTAMYLTRANSFERASE; LOSARTAN; OLMESARTAN; PLACEBO; PRODRUG; SARALASIN; WARFARIN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BRONCHITIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CROSSOVER PROCEDURE; DIET THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL ABSORPTION; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION RISK; SODIUM RESTRICTION; STATISTICAL SIGNIFICANCE; VERTIGO;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; IMIDAZOLES; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0036107461     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001391     Document Type: Article

References (8)

1. Brunner HR. Olmesartan medoxomil: a new AT1 receptor antagonist for the treatment of hypertension. Introduction. J Hypertens 2001; 19 (Suppl): S1-S2.
2. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001; 19 (Suppl): S3-S14.
3. Laeis P, Ptichler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001; 19 (Suppl): S21-S32.
4. von Bergmann K et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 (Suppl): S33-S40.
5. Püchler K, Nussberger J, Laeis P, Witte P-U. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist in salt-restricted hypertensive patients. J Hypertens 1997; 15: 1809-1812.
6. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of the therapeutic dose range of an AT1 receptor antagonist. J Hypertens 2001; 19 (Suppl): S15-S20.
7. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (Suppl): Data on file, Sankyo. Study 866-305.
8. Püchler K, Laeis P, Stumpe KO. Dose related differences in blood pressure response are not related to adverse event incidence [poster]. ESH 11th European meeting on Hypertension, Milan, Italy, June 2001.